Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma
Author:
Van Treeck Benjamin J.,
Olave Maria C.ORCID,
Watkins Ryan D.,
Lu Haiyan,
Moreira Roger K.,
Mounajjed Taofic,
Johnson Michael J.ORCID,
Smith Carin Y.ORCID,
Ilyas Sumera I.ORCID,
Tran Nguyen H.ORCID,
Jenkins Sarah M.,
Reed Katelyn A.,
Smoot Rory,
Mahipal Amit,
Allende Daniela,
Graham Rondell P.ORCID
Reference23 articles.
1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management;Banales;Nat Rev Gastroenterol Hepatol,2020
2. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma;Khan;HPB (Oxford),2008
3. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma;Bridgewater;J Hepatol,2014
4. Biliary tract cancers in olmsted county, Minnesota, 1976-2008;Yang;Am J Gastroenterol,2012
5. Efficacy and safety of gemcitabine plus cisplatin as potential preoperative chemotherapy in locally advanced intrahepatic, perihilar, and mid-cholangiocarcinoma: a retrospective cohort study;Nooijen;Am J Clin Oncol,2021